Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are used to control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan.